...
CRSPMID

CRISPR Therapeutics AG

HealthcareBiotechnology
$60.14
$0.02(-2.59%)
52W$30.04
$78.48
FinancialsValuationvs ALNY
Updated Mar 1, 12:00 AM
RSI66
RS Rating65/99
Beta1.25
Volatility63%
F-Score2/9
Mkt Cap$5.6B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

CRISPR Therapeutics AG is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 16% provides fundamental context to the price action. Investors should exercise caution due to high volatility (63% annualized), which requires wider risk management.

Relative Strength
65
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.25
vs S&P 500
ABOVE MKT
52W Position
62%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$54.14
50 SMA > 100 SMA$57.11
100 SMA > 150 SMA$57.42
150 SMA > 200 SMA$54.84

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$52.45+14.66%ABOVE
50 SMA$54.14+11.09%ABOVE
100 SMA$57.11+5.31%ABOVE
150 SMA$57.42+4.74%ABOVE
200 SMA$54.84+9.66%ABOVE

Price Performance

1D-2.6%
1W+11.4%
1M+12.0%
3M+12.5%
6M+13.4%
YTD+11.8%
1Y+36.9%
3Y+6.8%
52-Week Trading Range62% from low
$60.14
52W Low$30.04
52W High$78.48

Technical Indicators

RSI (14)BULLISH
66.2
305070
VCP ScoreCOOL
4/10
Base depth: 27.0%

Risk Profile

Beta
1.25
52W Vol
63%
ATR
$3.00
Max DD (1Y)
-40%

Volume Analysis

Today
60
50D Avg
1.45M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q4'24-140%
$-0.44
Q1'25-10%
$-1.58
Q2'25-61%
$-2.40
Q3'25-16%
$-1.17
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+30.39%
5 Years:+37.31%
3 Years:+100.42%
TTM:-81.72%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-97.53%

Stock Price CAGR

10 Years:+15.62%
5 Years:-14.32%
3 Years:+6.83%
1 Year:+36.93%

Return on Equity

10Y Avg:-19.8%
5Y Avg:-13.9%
3Y Avg:-19.2%
Last Year:-25.5%

Key Metrics

Market Cap$5.6B
Gross Margin-26.4%
Net Margin-165.7%
Piotroski F-Score2/9

More CRSP Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CRSP vs ALNYALNYIONSARWRBEAM

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 65 meansCRSP outperformed 65% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.25 means 25% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is CRSP in an uptrend right now?

CRSP has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is CRSP overbought or oversold?

CRSP's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.

Is CRSP outperforming the market?

CRSP has a Relative Strength (RS) Rating of 65 out of 99. CRSP is performing about average compared to the market.

Where is CRSP in its 52-week range?

CRSP is trading at $60.14, which is 77% of its 52-week high ($78.48) and 62% above its 52-week low ($30.04).

How volatile is CRSP?

CRSP has a Beta of 1.25 and 52-week volatility of 63%. It's more volatile than the S&P 500 - expect bigger swings.